The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer
Open accessAbstract
Our understanding of the molecular mechanisms underlying the pharmacological actions of estrogen receptor (ER) ligands has evolved considerably in recent years. Much of this knowledge has come from a detailed dissection of the mechanism(s) of action of the Selective Estrogen Receptor Modulators (SERMs) tamoxifen and raloxifene, so called for their ability to function as ER agonists or antagonists depending on the tissue in which they operate. These mechanistic insights have had a significant impact on the discovery of second generation SERMs, some of which are in late stage clinical development for the treatment/prevention of breast cancer as well as other estrogenopathies. In addition to the SERMs, however, have emerged the Selective Estrogen Degraders (SERDs), which as their name suggests, interact with and facilitate ER turnover in cells. One drug of this class, fulvestrant, has been approved as a third line treatment for ER-positive metastatic breast cancer. Whereas the first generation SERMs/SERDs were discovered in a serendipitous manner, this review will highlight how our understanding of the molecular pharmacology of ER ligands has been utilized in the development of the next generation of SERMs/SERDs, some of which are likely to have a major impact on the pharmacotherapy of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Yeo, G. W., Coufal, N. G., Liang, T. Y., Peng, G. E., Fu, X.-D., & Gage, F. H. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1545 · Cited by 572
Cited by
Patel, H. K., & Bihani, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 499
Molecular mechanism of estrogen–estrogen receptor signaling
Yaşar, P., Ayaz, G., User, S. D., Güpür, G., & Muyan, M. (2017) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12006 · Cited by 482
Liang, J., & Shang, Y. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183708 · Cited by 314
Prossnitz, E. R., & Arterburn, J. B. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009712 · Cited by 258
Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor
Clark, A. R., & Belvisi, M. G. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.12.004 · Cited by 209
“It was serendipitously discovered that the estrogen receptor (ER) ligand, tamoxifen, exerts agonistic effects on the ER in bone but antagonistic effects in breast (McDonnell & Wardell, 2010).”
McDonnell, D. P., Wardell, S. E., & Norris, J. D. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00760 · Cited by 178
Self-citationWhat have we learned about GPER function in physiology and disease from knockout mice
Prossnitz, E. R., & Hathaway, H. J. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.06.014 · Cited by 157
“ER antagonists that result in ER degradation in all tissues are referred to as selective estrogen receptor downregulators (SERDs) [32, 33].”
BackgroundThe role of hypothalamic estrogen receptors in metabolic regulation
Frank, A., Brown, L. M., & Clegg, D. J. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.05.002 · Cited by 128
“Interestingly, while highly active estrogens such as 17 beta-estradiol (E2) function as ER ligands, many pharmacological, as well as environmental and food compounds, are capable of binding and promoting ER activity [36].”
InfluentialMinireview: Dynamic Structures of Nuclear Hormone Receptors: New Promises and Challenges
Simons, S. S., Edwards, D. P., & Kumar, R. (2014) · Molecular Endocrinology · doi:10.1210/me.2013-1334 · Cited by 88
“Also, several peptide probes have been identified that recognize different conformations of SRM-bound SHRs and selectively disrupt receptor-coregulatory protein complexes in a tissue-specific manner (3, 63).”
BackgroundColón, J. M., González, P. A., Cajigas, Á., Maldonado, W. I., Torrado, A. I., Santiago, J. M., Salgado, I. K., & Miranda, J. D. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.006 · Cited by 19
“35 mediated neuroprotective effects and sex response differences, is that the differential effect could be associated to the expression of co-activators and co-repressors in male and female rats, which facilitate or inhibit transcription depending on tissue type (Lonard and Smith, 2002; McDonnell and Wardell, 2010).”
Background
Metadata
- Authors
- McDonnell, D. P., & Wardell, S. E.
- Venue
- Current Opinion in Pharmacology
- Publisher
- Elsevier BV
- Published
- 2010-12
- Volume
- 10
- Issue
- 6
- Pages
- 620-628
- ISSN
- 1471-4892 (ISSN-L)
- OpenAlex
- W2061671852
- Cited by
- 203
- References
- 3
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.